164 related articles for article (PubMed ID: 21512403)
1. Human immunodeficiency virus infection and non-small cell lung cancer: survival and toxicity of antineoplastic chemotherapy in a cohort study.
Makinson A; Tenon JC; Eymard-Duvernay S; Pujol JL; Allavena C; Cuzin L; Poizot-Martin I; de la Tribonnière X; Cabié A; Pugliese P; Reynes J; Le Moing V
J Thorac Oncol; 2011 Jun; 6(6):1022-9. PubMed ID: 21512403
[TBL] [Abstract][Full Text] [Related]
2. Effect of highly active antiretroviral therapy on survival of HIV infected patients with non-small-cell lung cancer.
Lavolé A; Chouaïd C; Baudrin L; Wislez M; Raguin G; Pialoux G; Girard PM; Milleron B; Cadranel J
Lung Cancer; 2009 Sep; 65(3):345-50. PubMed ID: 19135758
[TBL] [Abstract][Full Text] [Related]
3. Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort Study.
Simcock M; Blasko M; Karrer U; Bertisch B; Pless M; Blumer L; Vora S; Robinson JO; Bernasconi E; Terziroli B; Moirandat-Rytz S; Furrer H; Hirschel B; Vernazza P; Sendi P; Rickenbach M; Bucher HC; Battegay M; Koller MT;
Antivir Ther; 2007; 12(6):931-9. PubMed ID: 17926647
[TBL] [Abstract][Full Text] [Related]
4. Effect of HIV on survival in patients with non-small-cell lung cancer in the era of highly active antiretroviral therapy: a population-based study.
Rengan R; Mitra N; Liao K; Armstrong K; Vachani A
Lancet Oncol; 2012 Dec; 13(12):1203-9. PubMed ID: 23164952
[TBL] [Abstract][Full Text] [Related]
5. Risk of non-AIDS-defining cancers among HIV-1-infected individuals in France between 1997 and 2009: results from a French cohort.
Hleyhel M; Hleyhel M; Bouvier AM; Belot A; Tattevin P; Pacanowski J; Genet P; De Castro N; Berger JL; Dupont C; Lavolé A; Pradier C; Salmon D; Simon A; Martinez V; Spano JP; Costagliola D; Grabar S;
AIDS; 2014 Sep; 28(14):2109-18. PubMed ID: 25265077
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of ERCC2 haplotype-tagging single nucleotide polymorphisms in patients with unresectable non-small cell lung cancer treated with first-line platinum-based chemotherapy.
Kim SH; Lee GW; Lee MJ; Cho YJ; Jeong YY; Kim HC; Lee JD; Hwang YS; Kim IS; Lee S; Oh SY
Lung Cancer; 2012 Sep; 77(3):578-84. PubMed ID: 22608006
[TBL] [Abstract][Full Text] [Related]
7. Mortality in an urban cohort of HIV-infected and at-risk drug users in the era of highly active antiretroviral therapy.
Kohli R; Lo Y; Howard AA; Buono D; Floris-Moore M; Klein RS; Schoenbaum EE
Clin Infect Dis; 2005 Sep; 41(6):864-72. PubMed ID: 16107987
[TBL] [Abstract][Full Text] [Related]
8. Strong impact of highly active antiretroviral therapy on survival in patients with human immunodeficiency virus-associated Hodgkin's disease.
Hoffmann C; Chow KU; Wolf E; Faetkenheuer G; Stellbrink HJ; van Lunzen J; Jaeger H; Stoehr A; Plettenberg A; Wasmuth JC; Rockstroh J; Mosthaf F; Horst HA; Brodt HR
Br J Haematol; 2004 May; 125(4):455-62. PubMed ID: 15142115
[TBL] [Abstract][Full Text] [Related]
9. Total lymphocyte count as a possible surrogate of CD4 cell count to prioritize eligibility for antiretroviral therapy among HIV-infected individuals in resource-limited settings.
Bedell R; Heath KV; Hogg RS; Wood E; Press N; Yip B; O'Shaughnessy MV; Montaner JS
Antivir Ther; 2003 Oct; 8(5):379-84. PubMed ID: 14640384
[TBL] [Abstract][Full Text] [Related]
10. Leptomeningeal carcinomatosis in non-small-cell lung cancer patients: impact on survival and correlated prognostic factors.
Lee SJ; Lee JI; Nam DH; Ahn YC; Han JH; Sun JM; Ahn JS; Park K; Ahn MJ
J Thorac Oncol; 2013 Feb; 8(2):185-91. PubMed ID: 23328548
[TBL] [Abstract][Full Text] [Related]
11. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.
Dudek AZ; Kmak KL; Koopmeiners J; Keshtgarpour M
Lung Cancer; 2006 Jan; 51(1):89-96. PubMed ID: 16290256
[TBL] [Abstract][Full Text] [Related]
12. Human immunodeficiency virus-associated primary lung cancer in the era of highly active antiretroviral therapy: a multi-institutional collaboration.
D'Jaen GA; Pantanowitz L; Bower M; Buskin S; Neil N; Greco EM; Cooley TP; Henry D; Stem J; Dezube BJ; Stebbing J; Aboulafia DM
Clin Lung Cancer; 2010 Nov; 11(6):396-404. PubMed ID: 21062730
[TBL] [Abstract][Full Text] [Related]
13. Concurrent chemoradiotherapy with 5-fluorouracil and mitomycin C for invasive anal carcinoma in human immunodeficiency virus-positive patients receiving highly active antiretroviral therapy.
Fraunholz I; Weiss C; Eberlein K; Haberl A; Rödel C
Int J Radiat Oncol Biol Phys; 2010 Apr; 76(5):1425-32. PubMed ID: 19744801
[TBL] [Abstract][Full Text] [Related]
14. The impact of malnutrition on survival and the CD4 count response in HIV-infected patients starting antiretroviral therapy.
Paton NI; Sangeetha S; Earnest A; Bellamy R
HIV Med; 2006 Jul; 7(5):323-30. PubMed ID: 16945078
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors after non-Hodgkin lymphoma in patients infected with the human immunodeficiency virus: Aquitaine Cohort, France, 1986-1997. Groupe d'Epidémiologie Clinique du SIDA en Aquitaine (GECSA).
Thiessard F; Morlat P; Marimoutou C; Labouyrie E; Ragnaud JM; Pellegrin JL; Dupon M; Dabis F
Cancer; 2000 Apr; 88(7):1696-702. PubMed ID: 10738229
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of C-reactive protein and smoking in patients with advanced non-small cell lung cancer treated with first-line palliative chemotherapy.
Koch A; Fohlin H; Sörenson S
J Thorac Oncol; 2009 Mar; 4(3):326-32. PubMed ID: 19155996
[TBL] [Abstract][Full Text] [Related]
17. Effect of protease inhibitor-based highly active antiretroviral therapy on survival in HIV-associated advanced Kaposi's sarcoma patients treated with chemotherapy.
Leitch H; Trudeau M; Routy JP
HIV Clin Trials; 2003; 4(2):107-14. PubMed ID: 12671778
[TBL] [Abstract][Full Text] [Related]
18. Survival without common toxicity criteria grade 3/4 toxicity for pemetrexed compared with docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC): a risk-benefit analysis.
Pujol JL; Paul S; Chouaki N; Peterson P; Moore P; Berry DA; Salzberg M
J Thorac Oncol; 2007 May; 2(5):397-401. PubMed ID: 17473654
[TBL] [Abstract][Full Text] [Related]
19. Interactions between cytotoxic chemotherapy and antiretroviral treatment in human immunodeficiency virus-infected patients with lung cancer.
Makinson A; Pujol JL; Le Moing V; Peyriere H; Reynes J
J Thorac Oncol; 2010 Apr; 5(4):562-71. PubMed ID: 20195169
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy.
Kesselring AM; Wit FW; Sabin CA; Lundgren JD; Gill MJ; Gatell JM; Rauch A; Montaner JS; de Wolf F; Reiss P; Mocroft A;
AIDS; 2009 Aug; 23(13):1689-99. PubMed ID: 19487907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
